2-[(4-Phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D 4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl) piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist

Journal of Medicinal Chemistry

Volumn 49, Issue 13, 2006, Pages 3938-3947

  Enguehard Gueiffier, Cécile ^a   Hübner, Harald ^c   El Hakmaoui, Ahmed ^d   Allouchi, Hassan ^b   Gmeiner, Peter ^c   Argiolas, Antonio ^e   Melis, Maria Rosaria ^e   Gueiffier, Alain ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b e mail: Chrusciel Univ Toursfr   (France)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d HASSAN II UNIVERSITY OF CASABLANCA   (Morocco)

^e UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(4 PHENYLPIPERAZIL 1 YL)METHYL]IMIDAZO(DI)AZINE DERIVATIVE; 2 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YLMETHYL]IMIDAZO[1,2 A]PYRIDINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; A 412997; A 419227; ABT 724; CLOZAPINE; CP 226269; DOPAMINE 4 RECEPTOR; DOPAMINE 4 RECEPTOR ANTAGONIST; DOPAMINE RECEPTOR AFFECTING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; FAUC 113; FAUC 299; FAUC 319; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HALOPERIDOL; IMIDAZO[1,2 A]PYRIDINE DERIVATIVE; KETANSERIN; PARTIAL AGONIST; PD 168077; PD 186077; PRAZOSIN; QUINPIROLE; SPIPERONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING COMPETITION; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG COMPETITION; DRUG INHIBITION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; MALE; MITOGENESIS; NONHUMAN; PENIS ERECTION; RAT; RECEPTOR AFFINITY;

ANIMALS; CATTLE; CHO CELLS; CRICETINAE; CRICETULUS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; IMIDAZOLES; IMPOTENCE; LIGANDS; MALE; MITOSIS; PENILE ERECTION; PIPERAZINES; PYRIDINES; PYRROLES; RADIOLIGAND ASSAY; RATS; RECEPTORS, DOPAMINE D4; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33745659402     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060166w     Document Type: Article

References (52)

1. Seeman, P.; Van Tol, H. H. Dopamine receptor pharmacology. Trends Pharmacol. Sci. 1994, 15, 264-270.
2. Hartman, D. S.; Civelli, O. Dopamine receptor diversity: molecular and pharmacological perspectives. Prog. Drug Res. 1997, 48, 173-194.
3. Missale, C.; Nash, S. R.; Robinson, S. W.; Jaber, M.; Caron, M. G. Dopamine receptors: from structure to function. Physiol. Rev. 1998, 78, 189-225.
4. 4 receptor a controversial therapeutic target. Drugs Future 2000, 25, 587-611.
5. 4 (DRD4) gene. Hum. Mol. Genet. 1993, 2, 767-773.
6. 4 receptor antagonists in the treatment of schizophrenia. Expert Opin. Invest. Drugs 2002, 3, 101-105.
7. 4 receptor gene (DRD4) with attention deficit hyperactivity disorder (ADHD). Mol. Psychiatry 2000, 5, 531-536.
8. 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991, 350, 610-614.
9. 4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning. J. Med. Chem. 2004, 47, 2348-2355.
10. 4 receptor antagonists: review of structure-activity relationships. Curr. Med. Chem.: Cent. Nerv. Syst. Agents 2002, 2, 259-274.
11. 4 receptor agonists. Curr. Med. Chem. 2006.
12. 4 receptors by ABT-724 induces penile erection in rats. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 6758-6763.
13. 4 receptor agonist, induces penile erection when injected into the paraventricular nucleus of male rats. Neurosci. Lett. 2005, 379, 59-62.
14. Hsieh, G. C.; Hollingsworth, P. R.; Martino, B.; Chang, R.; Terranova, M. A.; et al. Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphine. J. Pharmacol. Exp. Ther. 2004, 308, 330-338.
15. 4 receptor agonist in rats. Pharmacol., Biochem. Behav. 2005, 82, 140-147.
16. 2-like receptor agonists accelerate barrier repair and inhibit the epidermal hyperplasia induced by barrier disruption. J. Invest. Dermatol. 2005, 125, 783-789.
17. 4 agonists. J. Med. Chem. 1997, 40, 1771-1772.
18. 4 receptor. Eur. J. Pharmacol. 2004, 497, 147-154.
19. 4 receptor: synthesis, ligand binding studies and comparison of molecular electrostatic potential maps. Bioorg. Med. Chem. Lett. 1999, 9, 97-102.
20. 4 receptor partial agonists: solid-phase synthesis, binding assays, and functional experiments. J. Med. Chem. 2000, 43, 4563-4569.
21. 4 receptor ligands leading to the complete antagonist 2-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a] pyridine (FAUC 213). J. Med. Chem. 2001, 44, 2691-2694.
22. Abadi, A. H. Phenylpiperazinylmethylheterocycle derivatives: synthesis and dopamine receptor binding profiles. Arch. Pharm. (Weinheim, Ger.) 2004, 337, 383-390.
23. Stanovnik, B.; Tisler, M. Synthesis of pyridazine derivatives-VIII: imidazo[1, 2-b]pyridazines and some tricyclic aza analogs. Tetrahedron 1967, 23, 387-395.
24. Barlin, G. B.; Davies, L. P.; Ireland, S. J.; Ngu-Schwemlein, M. M. L. Imidazo[1,2-b]pyridazines - XXII - Synthesis of some 2-aryl-3-methoxy-6- (pyridinylmethylthio and pyridinylmethylamino)imidazo[1,2-b]pyridazines and their interactions with central and mitochondrial (peripheral-type) benzodiazepine receptors. Aust. J. Chem. 1997, 50, 91-95.
25. Enguehard, C.; Hervet, M.; Thery, I.; Renou, J. L.; Fauvelle, F.; et al. (Hetero)arylation of 6-halogenoimidazo[1,2-a]pyridines differently substituted at C(2): Influence of the 2-substituent on the Suzuki cross-coupling reaction. Helv. Chim. Acta 2001, 84, 3610-3614.
26. Hervet, M.; Thery, I.; Gueiffier, A.; Enguehard-Gueiffier, C. Comparative study on the reactivity of 6-haloimidazo[1,2-a]pyridine derivatives towards Negishi- and Stille-coupling reactions. Helv. Chim. Acta 2003, 86, 3461-3469.
27. Zanon, J.; Klapars, A.; Buchwald, S. L. Copper-catalyzed domino halide exchange-cyanation of aryl bromides. J. Am. Chem. Soc. 2003, 125, 2890-2891.
28. Enguehard, C.; Allouchi, H.; Gueiffier, A.; Buchwald, S. L. Easy access to novel substituted 6-aminoimidazo[1,2-a]pyridines using palladium- and copper-catalyzed aminations. J. Org. Chem. 2003, 68, 4367-4370.
29. Kazock, J.-Y.; Enguehard-Gueiffier, C.; Thery, I.; Gueiffier, A. From the particular reactivity of 8-halogenoimidazo[1,2-a]pyridine towards copper and palladium catalyzed aminations. Bull. Chem. Soc. Jpn. 2006, 79, 775-779.
30. Antilla, J. C.; Klapars, A.; Buchwald, S. L. The copper-catalyzed N-arylation of indoles. J. Am. Chem. Soc. 2002, 124, 11684-11688.
31. Antilla, J. C.; Baskin, J. M.; Barder, T. E.; Buchwald, S. L. Copper-diamine-catalyzed N-arylation of pyrroles, pyrazoles, indazoles, imidazoles, and triazoles. J. Org. Chem. 2004, 69, 5578-5587.
32. Enguehard, C.; Allouchi, H.; Gueiffier, A.; Buchwald, S. L. Ipso- or erne-substitutions of 6-haloimidazo[1,2-a]pyridine derivatives with different azoles depending on the reaction conditions. J. Org. Chem. 2003, 68, 5614-5617.
33. Kazock, J.-Y.; Enguehard-Gueiffier, C.; Thery, I.; Gueiffier, A. Evaluation of the 2-substituent effect on the reactivity of the 8-haloimidazo[1,2-a]pyridine series towards Suzuki-type cross-coupling reaction. Bull. Chem. Soc. Jpn. 2005, 78, 154-159.
34. 2B subtypes in a heterologous cell line. Mol. Endocrinol. 1992, 6, 920-926.
35. 2 receptor. Eur. J. Pharmacol. 1992, 225, 331-337.
36. 4 receptor variants. J. Neurochem. 1995, 65, 1157-1165.
37. 3 subtype. J. Med. Chem. 2000, 43, 756-762.
38. 4 receptors. Eur. J. Pharmacol. 1995, 290, 29-36.
39. 2 dopamine receptors. Mol. Pharmacol. 1994, 45, 51-60.
40. 3 receptor antagonists and partial agonists. J. Med. Chem. 2002, 45, 4594-4597.
41. 2long dopamine receptors expressed in recombinant cells. Br. J. Pharmacol. 1996, 118, 1544-1550.
42. 44 receptors: actions of antiparkinsonian and antipsychotic agents. J. Pharmacol. Exp. Ther. 1997, 282, 181-191.
43. Argiolas, A.; Melis, M. R. Central control of penile erection: role of the paraventricular nucleus of the hypothalamus. Prog. Neurobiol. (Oxford) 2005, 76, 1-21.
44. RN1 reactions. Tetrahedron 1991, 47, 5173-5184.
45. Terme, T.; Galtier, C.; Maldonado, J.; Crozet, M. P.; Gueiffier, A.; et al. Synthesis of 2-substituted-3-nitroimidazo[1,2-b]pyridazines as potential biologically active agents. J. Heterocycl. Chem. 2002, 39, 173-177.
46. Sablayrolles, C.; Cros, G. H.; Milhavet, J. C.; Rechenq, E.; Chapat, J. P.; et al. Synthesis of imidazo[1,2-a]pyrazine derivatives with uterine-relaxing, antibronchospastic, and cardiac-stimulating properties. J. Med. Chem. 1984, 27, 206-212.
47. Gueiffier, A.; Blache, Y.; Chapat, J. P.; Elhakmaoui, A.; Essassi, E. M.; et al. Synthesis and antiviral activity of 2 and 3-substituted imidazolo[1,2-a]pyrimidine. Nucleosides Nucleotides 1995, 14, 551-554.
48. Lowry, O. H.; Rosebrough, N. J.; Fair, A. L.; Randall, R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275.
49. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
50. Melis, M. R.; Argiolas, A.; Gessa, G. L. Apomorphine-induced penile erection and yawning: site of action in brain. Brain Res. 1987, 415, 98-104.
51. Melis, M. R.; Argiolas, A. Dopamine and sexual behavior. Neurosci. Biobehav. Rev. 1995, 19, 19-38.
52. Pellegrino, L. J.; Cushman, A. J. A Stereotaxic Atlas of the Rat Brain; Meredith: New York, 1971.